Order Duprost | Avodart 0.5 mg

Generic Dutasteride (Duprost) for ordering online


Active substance: Dutasteride
U.S. Brand: Avodart
Indian Brand: Duprost
Made by:
Strength: 0.5 mg
Form release: blister with 10 capsules
Shipping time: 7 – 21 days
Best price: 0.55 USD
Order:


DescriptionHow to take?Common Side EffectsLatest New'sPhoto's

Duprost 0.5 mg Capsule is used in the treatment of benign prostatic hypertrophy (prostate enlargement). This medicine should be used only by men. Women and children are advised not to handle this medicine since there is a chance of absorption through the skin.

Duprost (Dutasteride) is to used to treat enlargement of prostate gland in BPH, reduce the problem of urinary blockage and the need for prostate surgery. Duprost is a medication designed for men only.

Duprost can lower the levels of the DHT hormone, which is the major cause of prostate growth. Duprost (Dutasteride) prevents the conversion of testosterone to dihydrotestosterone (DHT). DHT is involved in the development of benign prostatic hyperplasia and hair loss.

Duprost can also be used in the treatment of hair loss in mens. It may take 3-6 months to see any significant results after taking the medication.

The drug is available in the form of capsule under the following brand name and strength on our website:

  • Duprost – 0.5 mg Capsule

Buy Duprost – 0.5 mg online wemailmd.com.

The dosage depends upon the various factors such as age, weight, medical condition and your response to the treatment. Therefore, your doctor will decide the correct dose. Take the dose exactly as prescribed by the doctor. Never take two capsules at one time to double the doses.

Diarrhea, nausea, vomiting, dizziness and rash are the common side effects of Dutas. If any of these effects continues for a long time or deteriorate, contact your doctor immediately.

Beware ! Some medicines for prostate hypertrophy increase risk of Diabetes

Prescribed drugs to help them urinate are a third more at risk of type 2 diabetes- Research shows

Men who take medication to reduce their symptoms of prostate disease may be more likely to develop type 2 diabetes, research suggests.

Patients with enlarged prostates who are prescribed drugs called 5-alpha-reductase inhibitors are around a third more at risk of the condition.

They reduce the production of androgens, a hormone which help to boost urinary flow, a common problem among men with enlarged prostates.

But these drugs – which include finasteride and dutasteride – may slow metabolism and reduce the body’s insulin sensitivity, which can trigger type 2 diabetes.

The research was carried out by the University of Edinburgh and University College London. It was led by Professor Ruth Andrew, a personal chair of pharmaceutical endocrinology at Edinburgh.

‘We found that commonly prescribed medications for prostate disease can increase risk of type 2 diabetes,’ Professor Andrew said.

The 5-alpha-reductase inhibitors are often prescribed to treat benign prostatic hyperplasia (BPH), the medical term for an enlarged prostate.

This becomes more common with age, with an estimated prevalence of between eight and 60 per cent in men aged 90.

To determine the health effects of the drug, the researchers analysed the health records of 55,275 men in the UK who had been prescribed 5-alpha-reductase inhibitors for their BPH over 11 years.

Results – published in the British Medical Journal – revealed the drugs raise a man’s risk of developing type 2 diabetes by around one-third.

Dutasteride Market Rise

TF MI recently introduced Global Dutasteride Market study with in-depth overview, describing about the Product / Industry Scope and elaborates market outlook and status to 2023. The market Study is segmented by key regions which is accelerating the marketization. At present, the market is developing its presence and some of the key players from the complete study are GSK, Bionpharma, Rising Pharmaceuticals, Teva, Mylan, Zydus, Amneal Pharma, Apotex, Marksans Pharma & Breckenridge Pharmaceutical etc.

Request Sample of Global Dutasteride Market Research Report 2019 @: https://www.htfmarketreport.com/sample-report/1726006-global-dutasteride-market

The global Dutasteride market is valued at xx million US$ in 2018 is expected to reach xx million US$ by the end of 2025, growing at a CAGR of xx% during 2019-2025. This report focuses on Dutasteride volume and value at global level, regional level and company level. From a global perspective, this report represents overall Dutasteride market size by analyzing historical data and future prospect. Regionally, this report focuses on several key regions: North America, Europe, China and Japan. At company level, this report focuses on the production capacity, ex-factory price, revenue and market share for each manufacturer

This report studies the Global Dutasteride market size, industry status and forecast, competition landscape and growth opportunity. This research report categorizes the Global Dutasteride market by companies, region, type and end-use industry.

Browse 100+ market data Tables and Figures spread through Pages and in-depth TOC on ” Dutasteride Market by Type (, Avodart & Generic Avodart), by End-Users/Application (Hospital & Drug store), Organization Size, Industry, and Region – Forecast to 2023″. Early buyers will receive 10% customization on comprehensive study.

In order to get a deeper view of Market Size, competitive landscape is provided i.e. Revenue (Million USD) by Players (2013-2018), Revenue Market Share (%) by Players (2013-2018) and further a qualitative analysis is made towards market concentration rate, product/service differences, new entrants and the technological trends in future.

Generic copies of Avodart ready to hit market

Local pharmaceutical companies are preparing to release generic copies of Avodart (dutasteride), a treatment for enlarged prostate and hair loss, with reduced side effects.

The Ministry of Food and Drug Safety recently approved JW Pharmaceutical’s Jdart Tab., Dong-A ST’s Dutavan Plus Tab., Daehan New Pharm’s NPdart Tab., and JW Shinyak’s Neodart Tab.

These generics come in tablets, unlike Avodart and previous generics in soft capsules.

Soft capsules might be uncomfortable if they are stuck inside the mouth or the esophagus. The latest Avodart generics improved the patient convenience.

JW Pharm applied its technology called “self-micro emulsifying drug delivery system” (SMEDDS). SMEDDS converts insoluble agents to soluble ones, making body absorption quick.

The drugmaker unveiled the development of Jdart in March. It was the first in Korea to develop a dutasteride tablet.

JW Pharm completed the patent application for the dutasteride tablet in September last year. Dutasteride is effective in reducing urinary difficulties caused by enlarged prostate and acute cramps that make it difficult to release the urine. The agent is also known to prevent hair loss.

As Avodart’s patent expired in 2016, more than 30 generics have arrived in the market in severe competition.

GlaxoSmithKline, the supplier of Avodart, signed a contract with Teva-Handok to sell Avodart’s identical clone Zygard to counter attacks from generics.

To win the competition against the original treatment, Chong Kun Dang secured the generic exclusivity. Hanmi Pharmaceutical’s copy is only one-third of the size of Avodart.

With JW Pharm’s release of a similar tablet with minimized side effects, the competition in the Avodart-targeting market is likely to intensify.

lhs@docdocdoc.co.kr

Dutasteride (Duprost)
Average rating:  
 0 reviews